As Biotechnology businesses, AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) and Benitec Biopharma Limited (NASDAQ:BNTC), are affected by compare. This especially applies to their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AgeX Therapeutics Inc.||2||0.00||15.30M||-0.29||0.00|
|Benitec Biopharma Limited||1||0.00||6.26M||-0.82||0.00|
Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 shows the return on assets, net margins and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|AgeX Therapeutics Inc.||663,889,612.08%||-109.8%||-85.5%|
|Benitec Biopharma Limited||890,216,154.72%||0%||0%|
Insider & Institutional Ownership
Roughly 23.5% of AgeX Therapeutics Inc. shares are owned by institutional investors while 4.11% of Benitec Biopharma Limited are owned by institutional investors. Insiders owned roughly 0.2% of AgeX Therapeutics Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|AgeX Therapeutics Inc.||31.39%||-12.28%||-35.18%||-25.45%||0%||-2.01%|
|Benitec Biopharma Limited||26.87%||11.45%||-51.43%||-39.29%||-60.83%||-43.33%|
For the past year AgeX Therapeutics Inc. has stronger performance than Benitec Biopharma Limited
AgeX Therapeutics Inc. beats Benitec Biopharma Limited on 5 of the 9 factors.
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.